Antazoline mesylate

StatusCommercial
Development phase
Therapeutic cat.Other
Polymorphic form
CAS No.3131-32-6
Reference Product
Injectable Form
EU DMF readinessCheckbox
CEPCheckbox
CHINESE  DMFCheckbox
JAPANESE DMFCheckbox
KOREAN  DMFCheckbox
CANADIAN  DMFCheckbox
CADIFACheckbox
US DMF readinessCheckbox
OEB No.
Samples

Drug description

Polpharma API

  • Long experience in  in-house commercial manufacturing
  • In house  production of the whole product family (Antazolines)
  • No risk of  nitrosoamine presence
  • All intermediates  produced in-house

Disclaimer

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).

Have a question?
Our specialists will be happy to guide you through our cooperation process.
Contact us